Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background Evidence suggests higher RIF doses may be more effective for tuberculosis (TB) treatment. It is unclear if incremental RIF doses will increase risk of drug interactions through more potent induction of CYP3A4 enzymes and drug transporters. Some data suggest induction may be at maximum with standard dose (10mg/kg). Using standard, medium and high RIF…
Background The efficacy of antiretroviral therapy (ART) regimens used to treat people with HIV (PWH) on concomitant tuberculosis (TB) treatment has been evaluated in few clinical trials or programmatic data. We sought to assess virologic response 1 year after ART initiation in ART-naïve PWH with and without TB within the International epidemiology Databases to Evaluate…
Background Long-Acting antiretroviral therapy (LA-ART) is considered an integral tool to improve adherence and decrease stigma, but its global implementation has met barriers, including cost and resources for administration. The TLC-ART program, a public-private partnership, engineered a novel 3-drug combination nanoparticle (DcNP) for subcutaneous injection containing lopinavir (LPV), ritonavir (RTV), and tenofovir (TVF) “TLC-ART 101” bound…
Background Despite widespread immunity from SARS-CoV-2 vaccination and/or past infection, safe, effective, and convenient treatments for acute infection are still needed for individuals who remain at high risk for disease progression. Moreover, the risk of another coronavirus pandemic is an ongoing threat to global health. In this context, the development of pan-coronavirus therapeutics is a…
Background Favipiravir (FVP) is an anti-influenza agent but preclinical data support broad spectrum antiviral activity against RNA viruses including SARS-CoV-2 and haemorrhagic fevers. Pharmacokinetic (PK) data on the active form, favipiravir ribofuranosyl-5’-triphosphate (FRTP), are lacking in humans. We measured liquid plasma (LPL) FVP and intracellular FRTP measurements in PBMC and compared this with HemaSep filter…
Background The relevance of plasma (trough) concentrations of cabotegravir (CAB) and rilpivirine (RPV) with regard to sustained virologic suppression in people with HIV (PWH) on long-acting treatment (LA) is an ongoing matter of debate. We aimed to add to the currently available data by analyzing the association between CAB and RPV trough concentrations and viral…
Background The prevalence of obesity among women with HIV (WWH) is nearly 2-fold higher than in men with HIV, especially in sub-Saharan Africa. Obesity is closely associated with dysglycemia, and in the context of HIV frequently necessitates the co-administration of the first-line antiretroviral dolutegravir (DTG) and the insulin sensitizer metformin. However, a drug interaction exists…
Background Low plasma concentrations of LA CAB/RPV are associated with increased risk of virologic failure. However, trough LA CAB/RPV demonstrates high interindividual variability (CAB 31%, RPV 35%), and intraindividual variability (CAB 52%, RPV 29%) during the first 12 months of use. We sought to characterize the variability in trough plasma concentrations of CAB and RPV…
Background Approximately 58 million people are chronically infected with HCV globally, with approximately 1.5 million new infections per year and a disproportionate burden in low- and middle-income countries. Approved oral treatments, administered over 8 – 12 weeks, are highly effective demonstrating >98% sustained virological response (SVR) in RCTs. However, in some populations intention to treat…
Background In a Phase 2 study, oral once-weekly (QW) islatravir (ISL) plus lenacapavir (LEN) maintained high rates of viral suppression at 24 weeks in people with HIV-1 who were virologically suppressed (NCT05052996; Colson et al. CROI 2024; Abstract 208). To maintain high rates of viral suppression, it is important to ensure optimal drug concentrations in the…